Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Axial Biotherapeutics Named a “Fierce 15” Biotech Company of 2017 by FierceBiotech

Axial Biotherapeutics
Posted on: 03 Oct 17

Axial Biotherapeutics, a biotechnology company building a unique class of microbial-targeted therapeutics for neurological diseases, today announced that it has been named by FierceBiotech as one of 2017’s Fierce 15 biotechnology companies, designating it as a promising and innovative private biotech company whose research and development work has helped to transform the industry.

“It is an honor to be a recipient of this year’s FierceBiotech’s Fierce 15 award,” said David H. Donabedian, Ph.D., CEO and Co-Founder of Axial Biotherapeutics. “The credit goes to our dedicated team and advisors who have been working together to pioneer a new treatment path for neurological diseases and disorders through targeting the gut microbiome as well as building the company over the past year. This important recognition is also a testament to the groundbreaking research of our scientific co-founder Sarkis K. Mazmanian, Ph.D. which is the basis of our lead programs in Autism Spectrum Disorders and Parkinson’s Disease and we are commited to bring this exciting approach into the clinic in the near future.”

The Fierce 15 award celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s fifteenth annual Fierce 15 selection. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech
An internationally recognized daily report reaching a network of more than 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every business day, FierceBiotech and its family of publications covers the waterfront in drug development, from pre-clinical science to seed funding and venture capital, through IPOs and licensing, clinical testing, regulatory changes, M&A and beyond. Signup is free at

About Axial Biotherapeutics
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders.

View source version on

Business Wire

Last updated on: 03/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.